Table 2 Clinical characteristics of T-cell lymphoma patients with a TNFAIP3 mutation
From: TNFAIP3 mutation may be associated with favorable overall survival for patients with T-cell lymphoma
Sample ID | Histological subtype | Age, y | Gender | Country | Mutation sites | TNFAIP3 mutation | OS time (months) | Clinical outcome |
|---|---|---|---|---|---|---|---|---|
COSMIC dataset | ||||||||
 Patient 1 | PTCL-NOS | < 60 | Female | USA | CDS | g.305 A>G | – | Not relapse |
 Patient 2 | PTCL-NOS | ≥ 60 | Female | USA | CDS | g.1939 A>C | – | Not relapse |
 Patient 3 | PTCL-NOS | – | – | USA | CDS | g.1939 A>C | – | Not relapse |
 Patient 4 | CTCL | ≥ 60 | Male | USA | CDS | g.1307G>A, g.796dup, and g.732 C>A | – | Alive |
 Patient 5 | AITL | – | Female | USA | CDS | g.811 C>T | – | Alive |
 Patient 6 | CTCL | 67 | Male | USA | CDS | g.-15-1829_-15-1814del | – | – |
 Patient 7 | ATLL | 56 | Male | Japan | CDS | g.318dup | – | – |
 Patient 8 | CTCL | – | Female | USA | CDS | g.380T>G | – | – |
 Patient 9 | ATLL | – | – | Japan | CDS | g.1616_1617insT | – | – |
 Patient 10 | ATLL | – | – | Japan | CDS | g.1439_1440dup | – | – |
 Patient 11 | ATLL | 79 | Female | Japan | CDS | g.1667dup | – | – |
 Patient 12 | ATLL | – | – | Japan | CDS | g.1166 C>T | – | – |
GSE15842 dataset | ||||||||
 Patient 13 | PTCL-NOS | – | – | Germany | Intron | rs582757 | – | – |
 Patient 14 | PTCL-NOS | – | – | Germany | Intron | rs582757 | – | – |
JNU dataset | ||||||||
 Patient 15 | T-LBL | 69 | Female | China | Promoter | g.3918 C>T | 98.9 | Death |
 Patient 16 | CTCL | 36 | Male | China | Promoter | g.3918 C>T and g.3637 T>A | 58.8 | Death |
 Patient 17 | T-LBL | 19 | Male | China | 3’UTR | g.3869 C>G | 94.3 | Alive |
 Patient 18 | T-LGLL | 27 | Male | China | Intron | g.13751 A>C | 97.1 | Alive |
 Patient 19 | T-LGLL | 40 | Female | China | Intron | g.13751 A>C | 118.5 | Alive |
 Patient 20 | T-LGLL | 50 | Female | China | Intron | g.13751 A>C, g.14244 C>T, and g.11822T>C | 102.4 | Alive |